Vidac Pharma
Xetra:T9GTel Aviv, Israel· Est.
Israeli biotech advancing metabolic reprogramming therapies for cancer and dermatology.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Israeli biotech advancing metabolic reprogramming therapies for cancer and dermatology.
OncologyDermatology
Technology Platform
Metabolic reprogramming using small‑molecule modulators that target key enzymes and signaling pathways to reverse the cancer cascade and induce cellular differentiation.
Opportunities
Successful Phase 2B outcomes could enable fast‑track regulatory approval in Europe and the U.S., while the metabolic platform may be applied to a broad range of oncology indications and combination therapies.
Risk Factors
Clinical efficacy of metabolic reprogramming remains unproven at scale; competition from established oncology players and the need for substantial financing to advance later‑stage trials pose significant risks.
Competitive Landscape
Vidac’s focus on metabolism differentiates it from immuno‑oncology and kinase‑inhibitor companies, though it competes with other biotech firms exploring metabolic targets such as IDH inhibitors and AMPK modulators.